Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation MYO Myomo posts narrow Q4 2025 EPS beat shares rise 552 percent on positive investor sentiment What is driving sentiment for Ambarella AMBA stock Leaps 20260427